HIPEC CENTRES
IN CHINA
China's academic cancer centres perform CRS-HIPEC at high volume, with outcomes comparable to leading Western programmes, at costs 60–80% below those in the United States and Western Europe — accessible to international patients through CancerFax.
analyticsAt a Glance
- check_circleMajor academic centres in Beijing, Shanghai, Guangzhou, and Chengdu perform hundreds of CRS-HIPEC procedures annually
- check_circleChinese peritoneal oncology surgeons trained at PSOGI-affiliated international centres bring global standards to domestic practice
- check_circleCosts range from USD 12,000–25,000 for a complete CRS-HIPEC course — compared to USD 60,000–150,000 in the United States
- check_circleCancerFax coordinates the full international patient pathway — record review, consultation, visa, translation, and follow-up
Why China Has Become a Major CRS-HIPEC Destination
China's academic cancer centres have developed high-volume peritoneal oncology programmes driven by two factors: the high incidence of colorectal, gastric, and ovarian cancer in the Chinese population, which generates large referral volumes; and deliberate investment by major academic medical centres in peritoneal oncology as a subspecialty, including international fellowship training for surgeons and dedicated peritoneal oncology wards.
“The surgeons at China's leading CRS-HIPEC centres did not just read about Sugarbaker's technique — many trained directly in programmes connected to the international PSOGI network and publish their outcomes in peer-reviewed journals.”
Scale and Volume: Why Experience Matters Here
High-volume CRS-HIPEC centres — those performing more than 20 cases per year — have been shown to have operative mortality rates below 2% and major complication rates 30–40% lower than low-volume centres. China's top peritoneal oncology programmes at CAMS, Fudan, and SYSUCC perform well above this threshold, with some units reporting 50–100+ CRS-HIPEC procedures annually.
Cost Advantage Without Quality Compromise
A complete CRS-HIPEC at a leading US cancer centre costs USD 60,000–150,000 in total hospital and physician fees. At a Tier 3A Chinese academic medical centre, the equivalent procedure costs USD 12,000–25,000 including operative fees, ICU, ward stay, and all post-operative care. The equipment, trained surgeons, and anaesthetic infrastructure are comparable — the cost differential reflects labour economics and institutional overhead, not quality.
Leading Chinese CRS-HIPEC Centres
The following academic medical centres operate established peritoneal oncology programmes with specific CRS-HIPEC capability and international patient infrastructure.
| Centre | City | Primary HIPEC Indications | Key Strengths |
|---|---|---|---|
| Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) | Beijing | CRC, ovarian, PMP, gastric, mesothelioma | National cancer flagship; largest overall oncology volume; dedicated peritoneal oncology unit; all histology types |
| Peking University Cancer Hospital | Beijing | CRC peritoneal metastases, ovarian, gastric | High CRC and gastric volume; bilingual surgeons; international patient coordination programme |
| Fudan University Shanghai Cancer Center | Shanghai | Ovarian, CRC, PMP, peritoneal mesothelioma | Leading gynaecological oncology CRS-HIPEC; OVHIPEC protocol implementation; Shanghai PSOGI partner |
| Sun Yat-sen University Cancer Center (SYSUCC) | Guangzhou | CRC, ovarian, gastric, appendiceal / PMP | South China reference centre; high gastric cancer volume; active HIPEC translational research |
| West China Hospital, Sichuan University | Chengdu | CRC, ovarian, gastric peritoneal metastases | Southwest China reference; large general oncology volume; growing dedicated peritoneal oncology programme |
| Zhongshan Hospital, Fudan University | Shanghai | CRC, gastric, hepatic involvement cases | Hepatobiliary integration; complex combined peritoneal + hepatic resections; leading surgical research output |
| Renji Hospital, Shanghai Jiao Tong University | Shanghai | Ovarian, CRC, peritoneal surface malignancies | Strong gynaecological oncology; laparoscopic CRS capability; international collaboration |
How International Patients Access CRS-HIPEC in China
The CancerFax pathway for CRS-HIPEC in China runs from initial record review to post-operative follow-up in 4–8 weeks.
- 1
Medical Record Submission
Upload CT/MRI, PET-CT, pathology (including IHC and molecular markers), operative reports from prior surgery, and treatment summaries to CancerFax. All languages accepted. CancerFax prepares a structured peritoneal oncology summary for the receiving centre.
- 2
Specialist PCI Review
CancerFax's clinical team reviews your imaging specifically for peritoneal distribution, estimated PCI, small-bowel involvement, and extra-abdominal disease. A preliminary eligibility summary is provided within 5 working days — based on the criteria used at specialist CRS-HIPEC centres, not general oncology practice.
- 3
Centre Matching and Cost Estimate
Based on your tumour type, PCI, and anatomy, CancerFax recommends the most appropriate Chinese centre. An itemised cost estimate covering diagnostic laparoscopy, CRS-HIPEC, ICU, ward stay, and post-operative care is provided before any commitment is made.
- 4
Remote Specialist Consultation
Video consultation with the CRS-HIPEC surgeon at the selected centre — with CancerFax medical interpreter for Chinese-language consultations. The surgeon reviews your imaging, confirms eligibility assessment, and issues a formal treatment proposal.
- 5
Visa and Travel Coordination
CancerFax issues a hospital invitation letter for the Chinese medical visa application. Ground logistics — airport transfer, hotel near the hospital, hospital registration, interpreter booking — are coordinated simultaneously.
- 6
Diagnostic Laparoscopy and CRS-HIPEC
On arrival, diagnostic laparoscopy (Day 1–3) confirms eligibility and records the definitive PCI. If confirmed eligible, CRS-HIPEC is performed within 3–7 days. Hospital stay of 7–14 days follows. Post-operative CT before discharge.
- 7
Remote Post-Operative Follow-Up
CancerFax coordinates remote review of your 4–6 week CT scan by the treating centre. English procedure report and follow-up imaging report are forwarded to your home oncologist. Adjuvant chemotherapy coordination is facilitated.
China CRS-HIPEC: Key Reference Numbers
Practical benchmarks for international patients planning CRS-HIPEC in China.
- USD 12,000–25,000Complete CRS-HIPEC cost range in ChinaIncludes operative fees, anaesthesia, ICU, 7–14 day ward stay, and post-operative imaging at Tier 3A academic centres. Complex cases (higher PCI, multiple visceral resections) at the higher end.
- 60–80%Cost saving vs United StatesA CRS-HIPEC that costs USD 80,000–150,000 in a US academic medical centre costs USD 12,000–25,000 at an equivalent Chinese programme — the same operation, the same equipment, dramatically different labour and overhead economics.
- 3–4 weeksMinimum total stay for international patientsDiagnostic laparoscopy (1–2 days pre-surgery), CRS-HIPEC, and 7–14 days hospital recovery. Most international patients can return home 14–18 days after the operation for uncomplicated cases.
- <2%30-day operative mortality at top Chinese centresHigh-volume Chinese centres performing >30 CRS-HIPEC cases per year achieve operative mortality rates below 2% — consistent with published global benchmarks from PSOGI registry data.
More from the Peritoneal Oncology Resource Library
Continue exploring CRS-HIPEC — from patient selection and surgery to recovery and cost comparison.
Frequently Asked Questions
Common questions from international patients planning CRS-HIPEC in China.
About CRS-HIPEC in China
How do I know if a Chinese CRS-HIPEC centre is safe and experienced enough?
CancerFax evaluates centres using the same criteria applied by international peritoneal oncology networks: annual CRS-HIPEC volume (>20 cases/year minimum); published or audited outcome data; surgeon training at PSOGI-affiliated international programmes; dedicated peritoneal oncology infrastructure (separate ward, specialist nursing, 24-hour surgical cover); and availability of all surgical subspecialties needed for complex CRS (hepatobiliary, gynaecological, urological). Before recommending any centre, CancerFax verifies these criteria — we do not refer patients to centres we have not assessed. We can share the specific volume and complication data for recommended centres upon request.
Can I have diagnostic laparoscopy in China and then decide whether to proceed with CRS-HIPEC?
Yes — and this is the standard pathway at specialist Chinese peritoneal oncology centres. Diagnostic laparoscopy is performed as a separate surgical procedure 3–7 days before any planned CRS-HIPEC. The laparoscopy results are reviewed with you — and if the PCI is higher than expected, if the small-bowel mesentery is extensively involved, or if technical complete cytoreduction is not feasible, the operation is not proceeded with. The laparoscopy allows you to make a fully informed decision about CRS-HIPEC based on what is actually seen inside your abdomen, not what is estimated from CT. CancerFax plans all international CRS-HIPEC journeys to include this staged decision point.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Access CRS-HIPEC in China Through CancerFax
CancerFax reviews your PCI, imaging, and histology, matches you to the most appropriate Chinese CRS-HIPEC centre for your tumour type, and manages the complete international patient pathway from initial review through post-operative follow-up reporting to your home oncologist.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.